Dr. Tina Cascone outlines rationale & science behind neoadjuvant and perioperative immunotherapy for early stage NSCLC at #ASCO26. How do we isolate the value of the adjuvant component after pCR or non-pCR? How do we best escalate non-pCR? ADC? Vaccine? Insightful discussion.

Happy #PrideMonth from Sesame Street! Join us in celebrating and uplifting the LGBTQIA members of our community. ❤️🧡💛💚💙💜

Great discussion of KRAS G12D drugs by @KCArbourMD ends by highlighting the @MSK_DeptOfMed KRAS team

Another banner year at ASCO for our fellowship, with six Young Investigator Awards awarded to our trainees. Congratulations to our outstanding fellows on this well-deserved recognition!

ALK-Vac concurrent ALK TKI in advanced ALK NSCLC: safe/well tolerated & induced de novo immune responses to targeted resistance mutations. 93% responded to ≥1 antigen; 33% to all. Predominant Th17/Th17.1 CD4 expansion. Novel concept. Congratulations to authors! #ASCO26

📘 LIBRETTO-432 — NEJM nejm.org/doi/full/10.1056/NE… 📗 HARMONi-6 — The Lancet thelancet.com/journals/lance… 📘 RASolute 302 — NEJM nejm.org/doi/full/10.1056/NE… 📘 PROTEUS — NEJM nejm.org/doi/full/10.1056/NE…

1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26

Look at this @Hopkins_HemOnc alumni mentor in action! Way to go @DrArsenOsipov

IDEO Xchange: New Agents in #mNSCLC Phase 3 data from OptiTROP-Lung05 presented at ASCO 26 showed a PFS benefit for Sac-TMT  pembro in PD-L1  aNSCLC over pembro alone, with a trend toward OS benefit. Where do you see Sac-TMT pembro potentially fitting into the mNSCLC landscape for PD-L1  aNSCLC? Answer here: linkedin.com/posts/mnsclc-as… Xchange your vote with Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

IDEO Xchange: ALK  mNSCLC Updated data from the phase 3 #CROWN study presented at ASCO 26 showed a 7-year PFS of 55% in patients treated withlorlatinib, with the median not yet reached. What is your current preferred 1L therapy for patients with ALK #mNSCLC? Answer here: linkedin.com/posts/crown-asc… Xchange your vote with Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

Vote at the IDEO Xchange: Managing Asymptomatic Brain Mets in #NSCLC Phase 3 data from ASCO 26 showed upfront cranial RT reduced intracranial progression in patients with oncogene-driven NSCLC and asymptomatic brain mets but did not impact survival. Do you expect these data to impact how asymptomatic brain mets are managed? Vote here: linkedin.com/posts/nsclc-asc… Join Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

IDEO Xchange: Sequencing in ES-SCLC What would be your preferred sequencing strategy for ES-SCLC (assuming all are available)? Vote now: linkedin.com/posts/ideo-xcha… Join Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

Happening now at the IDEO Xchange: 1L IO in mNSCLC Which of the following is your preferred 1L treatment for STK-11, KEAP1, and/or KRAS-mutant mNSCLC? Answer here: linkedin.com/posts/ideo-xcha… Xchange your vote with Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

Happening now at the IDEO Xchange: Toxicity management in EGFRm mNSCLC In the context of EGFRm mNSCLC, which type of AE do your APPs find most challenging to manage and navigate? Vote here: linkedin.com/feed/update/urn… Xchange your thoughts with Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @IyengarPuneeth @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd

Join the IDEO Xchange tonight, right here on X. Participate in the #lungcancer conversation with Drs. @lungoncdoc @NarjustFlorezMD @HwakeleeMD @JuliaRotow @COlazagasti @IvyLorena_Md @marinagarassino @christine_lovly @LuisERaez1 @maraantonoff @AnaVManana @kamarroneMD @Noha_Soror @christinemphmd @IyengarPuneeth

🫁 #ASCO26 Developmental Therapeutics - Targeted Agents Oral Abstract session is also a can't miss! 🔖 Novel CD56, DLL3, and B7-H3 targeting ADCs with promising activity in SCLC, NSCLC, and NECs, as well as three KRAS G12D agents! #LCSM #LungCancer #SCLC @ASCO @OncBrothers @OncoAlert

Really thoughtful review from @raffcolo et al. in @Annals_Oncology challenging the ADC assumption: “more stable linker = better ADC.” The clinical story is nuanced. Some successful ADCs are relatively unstable, while more stable designs can shift toxicity rather than solve it. For example, ocular toxicity with stable auristatin ADCs being a striking example. And the humbling reminder: often <1% of an injected antibody/ADC dose reaches tumor. Maybe the goal isn’t maximum linker stability, but the right instability in the right biological context. annalsofoncology.org/article…

Attending the #AACR26 Major Symposium on Mechanisms of Resistance to RAS Inhibitors? Check out this spotlight on some recent @CD_AACR papers by session speaker @Sandra_Misale: The Far Side of Resistance to RAS Inhibitors doi.org/10.1158/2159-8290.CD…

Productive day of our #ASCOAdvocacy #California delegation advocating for #CancerResearch funding @NIH @theNCI, permanent telehealth coverage, and legislation to regulate #PriorAuthorization Strong representation from @UofCalifornia with @UCSF @UCLA @ucdavis @UCSD faculty and our friends from @kpnorcal @cityofhope & @ScrippsHealth @ASCO @ANCO_News @MOASC_Office @KelseyNatsuhara @charlesbnguyen @mpkosty @steveleeyc

🚨🔥@OncoAlert HOT OFF THE PRESS. 🟢JUST RELEASED @ASCO Annual Meeting #ASCO26 #Abstracts Titles. Looking forward & ready for: ⭐️GREAT: ✅Science ✅Research & ✅Education It’s an #EraOfHope for #Patients with #Cancer. 👇🏼 bit.ly/4eteq8A